

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Long-Read Sequencing Increases Diagnostic Yield for Pediatric Sensorineural Hearing Loss

Shelby E. Redfield¹, Wanqing Shao², Tieqi Sun¹, Adrian Pastolero¹, William J. Rowell³, Courtney E. French², Cillian Nolan³, J. Matthew Holt³, Christopher T. Saunders³, Cairbre Fanslow³, Eirini Maria Lampraki³, Christine Lambert³, Margaret Kenna^{1,2,4}, Michael Eberle³, Shira Rockowitz^{2,5,6}, Aiden Eliot Shearer^{*1,2,4}

1. Department of Otolaryngology and Communication Enhancement, Boston Children’s Hospital, Boston, MA, USA.
2. Children’s Rare Disease Collaborative, Department of Information Technology, Boston Children’s Hospital, Boston, MA, USA.
3. Pacific Biosciences, Menlo Park, CA, USA
4. Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA, USA.
5. Division of Genetics and Genomics, Department of Pediatrics, Boston Children’s Hospital, Boston, MA, USA.
6. The Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, MA 02115.

*Corresponding Author: Eliot Shearer, eliot.shearer@childrens.harvard.edu

23 **ORCID:**
24 Shelby Redfield: 0000-0002-3485-6654
25 Wanqing Shao: 0000-0003-4234-2095
26 Tieqi Sun: 0009-0005-3129-5109
27 Courtney French: 0000-0001-7620-1544
28 Cillian Nolan - 0009-0006-4092-5499
29 William Rowell: 0000-0002-7422-1194
30 J. Matthew Holt: 0000-0001-6411-9236
31 Christopher T. Saunders: 0000-0002-0726-7600
32 Eirini Maria Lampraki - 0000-0002-5688-8542
33 Margaret Kenna - 0000-0003-0851-9272
34 Michael Eberle: 0000-0001-8965-1253
35 Aiden Eliot Shearer: 0000-0001-8965-1253
36

37 **Abstract**

38

39 The diagnostic yield of genetic testing for pediatric sensorineural hearing loss (SNHL) has
40 remained at around 40% for over a decade despite newly discovered causative genes
41 and the expanded use of exome sequencing (ES). This stagnation may be due to (1) a
42 focus on coding regions of the genome and (2) an inability to resolve variants in complex
43 genomic regions due to reliance on short-read sequencing technologies. Short-read
44 genome sequencing (srGS) and long-read genome sequencing (lrGS) both provide
45 exonic single nucleotide variant (SNV) and small indel detection at the same sensitivity
46 as ES, but also evaluate intronic regions. lrGS provides improved resolution for structural
47 variants (SV) and repetitive genomic regions. We sought to investigate the potential utility
48 of lrGS in the diagnostic evaluation of a small cohort of patients with SNHL of unknown
49 etiology after ES and srGS. 19 pediatric patients with SNHL underwent lrGS via PacBio
50 SMRT sequencing. Sequencing data were processed using the PacBio WGS variant
51 pipeline. The diagnostic yield for this lrGS cohort was 4/19 (21%). Relevant variants
52 detected only with lrGS included a hemizygous deletion *in trans* with a missense variant
53 in an area of high genomic homology (*OTOA*) and two single nucleotide loss-of-function
54 variants *in trans* to a known copy-number-loss for a gene with a highly homologous
55 pseudogene (*STRC*). A complex inversion was identified in the *MITF* gene which was
56 also identified on post-hoc analysis by srGS. lrGS provides improved resolution for
57 complex genomic structural variation which may increase diagnostic yield for genetic
58 pediatric SNHL, and, potentially, rare disease more broadly.

59

60 **Keywords:** long read sequencing, sensorineural hearing loss, hereditary hearing loss

61 Introduction

62
63 Congenital sensorineural hearing loss (SNHL) affects as many as 1 in 500 infants in the
64 United States (Morton and Nance 2006) and a majority of these cases are attributable to
65 a Mendelian genetic etiology (Smith et al. 2005). The implementation of comprehensive
66 genetic testing for pediatric SNHL, typically via targeted SNHL gene panels or exome
67 sequencing (ES), results in an overall diagnostic yield of approximately 43% (Downie et
68 al. 2020; Perry et al. 2023; Rouse et al. 2022; Shearer 2024; Sloan-Heggen et al. 2016).
69 There is variation in yield based on clinical phenotype and in some populations, for
70 instance congenital severe to profound hearing loss, the diagnostic yield can approach
71 60% (Downie et al. 2020; Sloan-Heggen et al. 2016). This diagnostic yield is relatively
72 high compared to other neurodevelopmental disorders for which genetic testing is
73 routinely obtained, such as autism (17%) and epilepsy (24%) (Stefanski et al. 2021).
74 However, this means that up to 60% of children with a high *a priori* suspicion of a
75 hereditary SNHL still go undiagnosed (Kim et al. 2022; Retterer et al. 2016).

76 The most commonly applied testing methodology for the genetic diagnosis of SNHL is
77 targeted gene panels, which rely on short read (150-300bp) sequencing of a targeted list
78 of SNHL genes. Less frequently, pediatric patients with a primary indication of SNHL will
79 undergo ES, also using short-read sequencing technologies. Both gene panels and ES
80 are limited by (1) a focus on exonic or coding regions and nearby splice sites, and (2) low
81 resolution for complex structural variation that contributes to genetic disease. Short-read
82 genome sequencing (srGS), which is currently not commonly applied in the clinical
83 evaluation of individuals with SNHL, does provide effective coverage of intronic and
84 noncoding regions (Byrska-Bishop et al. 2022; Pagnamenta et al. 2023).

85 However, while srGS evaluates noncoding regions of the genome, it is often unable to
86 resolve areas of low complexity, high duplication rate, and structural variation (Chaisson
87 et al. 2019; Genomes Project et al. 2015). In fact, much of the human genome maps to
88 segmental duplications, or stretches of DNA over 1kb long with over 90% sequence
89 identity, that are highly mutable but very challenging to resolve using current
90 methodologies (Bailey et al. 2001; Vollger et al. 2023). Two genes that commonly cause
91 nonsyndromic SNHL, *OTOA* and *STRC*, map to a segmental duplication and highly
92 homologous pseudogene, respectively, and detecting pathogenic variants within these
93 genes is challenging (Abbasi et al. 2022; Shearer et al. 2014). This is particularly
94 important given that pathogenic variation in *STRC* is the second most common cause of
95 genetic SNHL (Shearer et al 2014).

96 Long-read genome sequencing (lrGS), by contrast, generates sequencing reads up to
97 several megabases long (Mahmoud et al. 2024; Mantere et al. 2019) and therefore has
98 high resolution for complex structural variation and repetitive genomic regions. Several
99 studies over the last few years have shown that long-read techniques have the capacity
100 to identify Mendelian etiology after standard sequencing techniques have failed, including
101 a handful of patients with SNHL (Conlin et al. 2022; Miller et al. 2021; Ohori et al. 2021;
102 Olivucci et al. 2024; Vache et al. 2020; Xie et al. 2020).

103 In this study, our goal was to evaluate the potential utility of lrGS for genetic diagnosis for
104 pediatric hearing loss in patients with nondiagnostic ES and srGS. We find that lrGS
105 provided significantly improved resolution for complex structural variation and, in this
106 cohort, substantially improved diagnostic yield over ES and srGS.

107

108 **Methods**

109

110 *Recruitment and Participants*

111

112 This research was approved by the Institutional Review Board at Boston Children's
113 Hospital (P00035179 and P00031494) and performed in partnership with the Children's
114 Rare Disease Cohort initiative. Pediatric patients with SNHL were recruited in the Boston
115 Children's Hospital Otolaryngology and Communication Enhancement clinical setting and
116 provided written informed consent to participate. Criteria for eligibility included having a
117 clinical diagnosis of SNHL that did not have a known genetic etiology; there were no
118 exclusions based on other clinical criteria, including age of onset, laterality or severity of
119 hearing loss, presence of syndromic features, or family history. All patients had diagnostic
120 work up for sensorineural hearing loss including audiometric testing and clinical
121 evaluation; many had additional diagnostic workup including congenital cytomegalovirus
122 (cCMV) testing and temporal bone imaging (CT and/or MRI).

123

124 *Genetic Testing Methodologies*

125

126 Prior to lrGS through this study, genetic testing methodologies varied based on individual
127 patient circumstances. Some probands had prior single gene sequencing or targeted
128 hearing loss gene panel sequencing on a clinical basis. All probands had research exome
129 sequencing, and most probands had srGS performed on a research basis prior to
130 research lrGS. Prior genetic testing, regardless of methodology, was deemed
131 nondiagnostic by the testing laboratory and clinical team.

132

133 *DNA Extraction, Sequencing, and Analysis*

134

135 DNA was extracted from whole blood using standard methods. 150bp paired end ES and
136 srGS was performed at GeneDx using Illumina sequencers. ES and srGS data were
137 processed using Illumina Dragen v3.9 as previously described (Rockowitz et al. 2020).
138 For PacBio sequencing, 12-15 kb insert SMRTbell libraries were prepared using the
139 SMRTbell prep kit 3.0. Long-read whole genome sequencing was performed using Single
140 Molecule, Real-Time (SMRT) sequencing at Pacific Biosciences ("PacBio,") (Menlo Park,
141 CA) using the PacBio Sequel II system to a depth of 24-32x coverage. Sequence data
142 was processed by PacBio variant pipeline. Unaligned HiFi reads in BAM format were
143 received from PacBio. Read alignment and variant calling were performed using PacBio
144 HiFi-human-WGS-WDL workflow v1.0.3. In short, HiFi reads were aligned to the GRCh38
145 (GCA_000001405.15) genome using pbmm2 v1.10.0. Single nucleotide variants, small
146 insertions and deletions were identified with DeepVariant v1.5.0 (Poplin et al. 2018).
147 Structural variants were called with pbsv v2.9.0. Copy number variations were called with
148 HiFiCNV v0.1.7. Short tandem repeat expansion was identified using TRGT v0.5.0. Small

149 variants and structural variants were jointly phased with HiPhase v0.10.2 (Holt et al.
150 2024), and phase haplotype tags (“HP”) were added to the aligned BAM file. Variant
151 calling results were further processed using in house bioinformatic pipelines and analyzed
152 via GeneDx Discovery Platform. For each candidate variant, sequencing reads were
153 visually reviewed using IGV v2.16.0.

154

155 *Clinical Confirmation and Return of Results*

156

157 Variant pathogenicity was determined according to the American College of Medical
158 Genetics and the Associations for Molecular Pathology guidelines as modified for SNHL-
159 specific considerations (Oza et al. 2018; Richards et al. 2015). Candidate variants that
160 were identified via research analysis of IrGS were clinically confirmed using an additional
161 clinical sample and orthogonal genetic testing method within a commercial genetic testing
162 laboratory (Prevention Genetics, Marshfield, WI) environment with Clinical Laboratory
163 Improvement Amendments (CLIA) approval. Clinically confirmed variant results were
164 returned to families and genetic counseling was provided by a certified and licensed
165 genetic counselor and otolaryngologist.

166

167

168 **Results**

169

170 *Subject Demographic and Clinical Characteristics*

171

172 Nineteen probands underwent IrGS through this study (**Table 1**). The median age at the
173 time of results was 7-years-old (with an interquartile range of 5.1-years-old to 9.7-years-
174 old). Fifteen (79%) probands had a bilateral symmetric SNHL, three (15.8%) had bilateral
175 asymmetric hearing loss, and one (5.2%) had unilateral SNHL with bilateral enlarged
176 vestibular aqueducts. Twelve probands (63%) had congenital onset SNHL, 2 (10.5%) had
177 prelingual SNHL, 3 (15.8%) had postlingual SNHL, and onset of SNHL was unknown for
178 2 probands (10.5%). Severity of SNHL was highly variable (**Supplemental Table 1**). Two
179 (10.5%) probands had an autosomal recessive family history of SNHL, two (10.5%) had
180 an autosomal dominant family history of SNHL, and 15 (78.9%) had no reported family
181 history. Five (33.3%) probands had notable extra-auditory clinical presentations including
182 hemolytic anemia; retinal dystrophy; global developmental delay; hypotonia, low vision,
183 and nystagmus, and hematuria in one proband each.

184

185 All probands had extensive genetic testing prior to IrGS, the primary indication for which
186 was SNHL. Three probands (15.8%) had single gene (GJB2) testing, four probands (21%)
187 had SNHL gene panel testing, 19 probands (100%) had exome sequencing, and 18
188 probands (94.7%) had short read genome sequencing. Testing was nondiagnostic for all
189 19 probands on initial analysis. Nine probands (47.4%) were identified to harbor a
190 heterozygous pathogenic or likely pathogenic variant in a gene that was associated
191 exclusively or primarily with autosomal recessive conditions, including two probands with
192 a heterozygous loss of *STRC* (full patient details are included in **Supp. Table 1**).

193

194 *Long Read Genome Sequencing:*

195
196 The median read length across 19 samples was 13.5 kb (1.2 kb standard deviation). The
197 median depth of coverage of LrGS across samples was 29.5x (3.5x standard deviation).
198 On average, per sample, 5,386,525 single nucleotide variants were detected (range
199 5,305,533-5,533,276) and 22,004 structural variants were detected (range 19,838-
200 23,049). The number of variants, both SNVs and SVs, detected through ES and srGS of
201 these same patients was significantly lower than for LrGS (**Table 2 and Supp. Table 2**).
202

203 LrGS and analysis was completed for 19 probands. Genetic variants were identified for 4
204 of the 19 probands that were assessed to be causative or potentially causative resulting
205 in a diagnostic yield of 21.1%.
206

207 **Case Vignettes**

208 *Case 1:*

209 Proband 1 is a with a bilateral mild-moderate SNHL who is otherwise healthy. Proband
210 referred bilaterally on the newborn hearing screen in the neonatal period. Two diagnostic
211 auditory brainstem response (ABR) tests in infancy showed a bilateral SNHL in the mild
212 range of severity. Subsequent behavioral audiometric evaluations in childhood have been
213 consistent with a stable bilateral mild sensorineural hearing loss. The proband has an
214 older sibling with a similar history and audiological profile. There is otherwise no family
215 history of SNHL. Proband had cytomegalovirus (CMV) testing in the newborn period that
216 was negative. She has not had diagnostic imaging of the inner ear. Research ES for
217 proband, sibling, and parents was nondiagnostic but did identify a heterozygous copy
218 number loss at chromosome 15q15.3 encompassing the *STRC* and *CATSPER2* genes.
219 No second variant was detected. SrGS did not identify any further notable variants.
220

221
222 LrGS identified a pathogenic nonsense mutation in trans with a hemizygous deletion of
223 *STRC* and *CATSPER2* (**Figure 1A**). The depth-based CNV caller HiFiCNV detected a
224 104 kb deletion (approx. chr15:43,566,001-43,670,000). On the other allele, DeepVariant
225 (Poplin et al. 2018) analysis identified the variant NM_153700.2:c.1228C>A, p.(Gln410*)
226 (chr15:43,616,338 G>A). This variant is absent from gnomAD, ClinVar, and LOVD and
227 results in a stop gain in an exon that is challenging to map with short reads due to a highly
228 similar paralog. Interestingly, phasing analysis using Paraphase (Chen et al. 2023)
229 enabled visualization of a single *STRC* haplotype and two pseudogene haplotypes of
230 *pSTRC* (**Figure 1A**). This phasing analysis of a complex region helps to confirm
231 segregation. Both *STRC* variants were clinically confirmed and disclosed to the family.
232 LrGS was able to help resolve this SNV when other methods could not, due to the highly
233 homologous pseudogene *pSTRC*.
234

235 *Case 2:*

236 Proband 2 is a male with a bilateral mild to moderate SNHL who is otherwise healthy. He
237 did not pass a newborn hearing screen. An ABR performed in infancy identified a mild
238 SNHL. A recent behavioral audiometric evaluation in childhood showed a bilateral mild to
239 moderate SNHL. The proband had negative CMV testing in the newborn period. He has
240 not had diagnostic imaging of the inner ear. Research trio ES identified a heterozygous

241 CNV at 15q15.3 encompassing the *STRC* and *CATSPER2* genes. SrGS was
242 nondiagnostic. Similar to Case 1, LrGS identified a single nucleotide variant in *STRC*
243 (NM_153700.2:c.3217C>T, p.(Arg1073*)) *in trans* to the CNV which was classified as
244 pathogenic. Following the identification of these *STRC* variants, another sibling to
245 proband 2 was born and identified to have a mild bilateral SNHL shortly after birth; results
246 of targeted *STRC* variant testing for this sibling are pending.

247
248

249 Case 3:

250 Proband 3 is a female with a bilateral SNHL. She did not pass a newborn hearing screen
251 bilaterally. Initial ABR in infancy identified a bilateral SNHL that was moderate in severity.
252 A recent hearing test in childhood demonstrated a slightly u-shaped audiogram
253 configuration in the moderate to moderately-severe range of severity. She had CMV
254 testing that was negative. She has not had diagnostic imaging of the inner ear. Targeted
255 gene panel testing identified a heterozygous likely pathogenic variant in *MYO7A* (**Supp.**
256 **Table 1.**) The proband's unaffected parent also harbored this variant. Research exome
257 and srGS were nondiagnostic with no further variants of interest identified.

258

259 LrGS identified a copy number variant (CNV) (loss of 769bp at chr16:21,735,945)
260 including exon 22 of *OTOA* *in trans* with a heterozygous missense variant
261 (NM_144672.3:c.2654A>G, p.(His885Arg)) in the *OTOA* gene (**Figure 1B**). This result
262 was deemed to be possibly/likely diagnostic of *OTOA*-associated nonsyndromic hearing
263 loss. However, the missense variant in *OTOA* is currently classified as a variant of
264 uncertain significance. *OTOA* is within a segmental duplication. Neither variant in *OTOA*
265 had been appreciated before LrGS; upon review, the srGS analysis pipeline had called the
266 His885Arg missense variant, but it had been filtered out of the list of candidate variants
267 due to low call quality (poor coverage and mapping quality). The CNV was detected only
268 by LrGS.

269

270 Case 4:

271 Proband 4 is a female with a bilateral asymmetric SNHL. She passed a newborn hearing
272 screen bilaterally. Failing a hearing screen in early childhood prompted audiological
273 assessment. Behavioral audiometry identified a mild low-frequency SNHL, which has
274 progressed slightly since first identified. In the right ear, hearing is in the moderate rising
275 to normal range of severity. In the left ear, hearing has been in the slight sloping to
276 moderate rising to normal range of severity. *GJB2* sequencing was negative. Research
277 ES was nondiagnostic.

278

279 LrGS identified a 403.2kb inversion (chr3:69977069_70380310inv) upstream of the *MITF*
280 gene predicted to impact alternatively spliced transcripts of *MITF*. Similar inversions have
281 not been reported before, so this variant was classified as a variant of uncertain
282 significance though it is suspected to be causative of the proband's SNHL. This copy-
283 neutral inversion was subsequently identified on srGS upon reanalysis of data using an
284 updated tertiary analysis pipeline.

285

286 Discussion

287
288 Despite increasing access to comprehensive genetic testing for pediatric SNHL patients,
289 the discovery of additional SNHL genes, and decreasing costs of testing, the diagnostic
290 yield of the genetic evaluation of SNHL remains at approximately 43% over the past
291 decade (Shearer 2024). While this diagnostic rate is high compared to other indications
292 for genomic testing in children (Malinowski et al. 2020; Manickam et al. 2021; Vandersluis
293 et al. 2020), there remains a gap between the actual diagnostic rate and the suspected
294 true prevalence of hereditary hearing loss (Smith et al. 2005). Furthermore, the
295 improvement in the diagnostic yield for hearing loss as well as other pediatric rare
296 diseases seems only modestly increased when comparing srGS to ES (Wojcik et al.
297 2024). Identifying the underlying cause of SNHL in pediatric patients is critical to providing
298 tailored, high-quality care. Determining the genetic etiology of SNHL facilitates accurate
299 genetic counseling and recurrence counseling, provides valuable information on
300 prognosis that may impact treatment decisions, and allows for the identification and
301 appropriate follow-up for children with syndromic SNHL. Ongoing clinical trials for
302 targeted gene therapies for DFNB9 further emphasize the utility of precision medicine in
303 the care of pediatric SNHL patients and the potential impact of an accurate genetic
304 diagnosis (Lv et al. 2024).

305
306 Given the relatively high prevalence of pediatric SNHL in the population, an increase in
307 the overall genetic diagnostic rate is poised to result in many more diagnoses per year, in
308 absolute terms. The *STRC* gene alone has a carrier frequency of approximately 1.5% in
309 the general population, and accounts for around 15% of all cases hereditary hearing loss
310 (Han et al. 2021; Perry et al. 2023; Shearer et al. 2014; Shubina-Oleinik et al. 2021; Sloan-
311 Heggen et al. 2016). However, due to the *STRC* pseudogene and complexity of this
312 genomic region, many commercial labs will only perform CNV analysis without
313 sequencing or omit *STRC* from gene panels altogether. We posit that *STRC* is, therefore,
314 meaningfully under-diagnosed. We performed lrGS for two unrelated probands with
315 congenital mild-moderate SNHL and a heterozygous loss of *STRC*, resulting in a high *a*
316 *priori* suspicion for a missing second *STRC* variant. lrGS confirmed that suspicion,
317 resolving loss-of-function SNVs *in trans* to a CNV for both probands. While less prevalent
318 than *STRC*-, *OTOA*-mediated hearing loss is likely underdiagnosed as well due to its
319 locus in a segmental duplication. Indeed, an estimated 7% of the human genome consists
320 of segmental duplications that are highly mutable (Vollger et al. 2023; Vollger et al. 2022).

321
322 This work underscores the promise of lrGS to improve detection of variants in complex
323 and difficult-to-resolve genomic regions and increase diagnostic yield. In this study, we
324 selected a cohort of 19 probands with pediatric SNHL who had already had extensive
325 genetic evaluation. We were able to identify four additional diagnoses and confirm a
326 complex structural variant, leading to a diagnostic rate of 21.1% using lrGS. Emerging
327 studies comparing the genetic diagnosis of rare disease using ES and srGS do not report
328 a significant improvement in the yield of srGS over ES (Chung et al. 2023). SrGS remains
329 more expensive than ES and more time-consuming to analyze. It is, in fact, not a part of
330 routine clinical care to order srGS across most clinical indications, including pediatric
331 SNHL. Sample sizes are small, but published rare disease studies using lrGS, including

332 this one, hint at the potential for improved yield over other methodologies (Mahmoud et
333 al. 2024; Miller et al. 2021; Pagnamenta et al. 2023; Xie et al. 2020).

334
335 LrGS, while not currently available on a clinical basis, offers a single test to identify SNV,
336 CNVS, small insertion and deletions, tandem repeats, SVs, and methylation changes
337 across both simple and complex genomic regions. In addition, this technology provides
338 phasing information which may be advantageous for discrimination of pathogenic
339 variation. For the patients in this small cohort, each had undergone extensive genetic
340 testing prior to lrGS. While lrGS remains costly compared to other testing modalities,
341 eliminating the use of other high-cost, low-yield tests such as srGS may ultimately be
342 more beneficial to all stakeholders.

343
344 Limitations of our study include the small cohort size as well as the selection of probands
345 for inclusion based on high *a priori* suspicion of a mendelian condition based on clinical
346 characteristics. Future work should include a larger sample size of less highly selected
347 patients with pediatric SNHL.

348 349 **Conclusions**

350
351 Long read sequencing, while not in use clinically, has shown promise as a single test
352 capable of detecting diverse genomic variant types in both simple and complex genomic
353 regions. We describe four diagnoses identified in a cohort of 19 pediatric patients with
354 SNHL who had undergone extensive nondiagnostic testing prior to lrGS, further
355 highlighting the promise of this technology to significantly increase diagnostic rates.

356 Bibliography

- 357
- 358 Abbasi W, French CE, Rockowitz S, Kenna MA, Eliot Shearer A (2022) Evaluation of copy
359 number variants for genetic hearing loss: a review of current approaches and
360 recent findings. *Hum Genet* 141: 387-400. [https://doi.org/10.1007/s00439-021-](https://doi.org/10.1007/s00439-021-02365-1)
361 [02365-1](https://doi.org/10.1007/s00439-021-02365-1)
- 362 Bailey JA, Yavor AM, Massa HF, Trask BJ, Eichler EE (2001) Segmental duplications:
363 organization and impact within the current human genome project assembly.
364 *Genome Res* 11: 1005-17. <https://doi.org/10.1101/gr.gr-1871r>
- 365 Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, Corvelo A, Clarke
366 WE, Musunuri R, Nagulapalli K, Fairley S, Runnels A, Winterkorn L, Lowy E,
367 Human Genome Structural Variation C, Paul F, Germer S, Brand H, Hall IM,
368 Talkowski ME, Narzisi G, Zody MC (2022) High-coverage whole-genome
369 sequencing of the expanded 1000 Genomes Project cohort including 602 trios.
370 *Cell* 185: 3426-3440 e19. <https://doi.org/10.1016/j.cell.2022.08.004>
- 371 Chaisson MJP, Sanders AD, Zhao X, Malhotra A, Porubsky D, Rausch T, Gardner EJ,
372 Rodriguez OL, Guo L, Collins RL, Fan X, Wen J, Handsaker RE, Fairley S,
373 Kronenberg ZN, Kong X, Hormozdiari F, Lee D, Wenger AM, Hastie AR, Antaki D,
374 Anantharaman T, Audano PA, Brand H, Cantsilieris S, Cao H, Cerveira E, Chen C,
375 Chen X, Chin CS, Chong Z, Chuang NT, Lambert CC, Church DM, Clarke L, Farrell
376 A, Flores J, Galeev T, Gorkin DU, Gujral M, Guryev V, Heaton WH, Korlach J,
377 Kumar S, Kwon JY, Lam ET, Lee JE, Lee J, Lee WP, Lee SP, Li S, Marks P, Viaud-
378 Martinez K, Meiers S, Munson KM, Navarro FCP, Nelson BJ, Nodzak C, Noor A,
379 Kyriazopoulou-Panagiotopoulou S, Pang AWC, Qiu Y, Rosanio G, Ryan M, Stutz
380 A, Spierings DCJ, Ward A, Welch AE, Xiao M, Xu W, Zhang C, Zhu Q, Zheng-
381 Bradley X, Lowy E, Yakneen S, McCarroll S, Jun G, Ding L, Koh CL, Ren B, Flicek
382 P, Chen K, Gerstein MB, Kwok PY, Lansdorp PM, Marth GT, Sebat J, Shi X, Bashir
383 A, Ye K, Devine SE, Talkowski ME, Mills RE, Marschall T, Korbel JO, Eichler EE,
384 Lee C (2019) Multi-platform discovery of haplotype-resolved structural variation in
385 human genomes. *Nat Commun* 10: 1784. [https://doi.org/10.1038/s41467-018-](https://doi.org/10.1038/s41467-018-08148-z)
386 [08148-z](https://doi.org/10.1038/s41467-018-08148-z)
- 387 Chen X, Harting J, Farrow E, Thiffault I, Kasperaviciute D, Genomics England Research
388 C, Hoischen A, Gilissen C, Pastinen T, Eberle MA (2023) Comprehensive SMN1
389 and SMN2 profiling for spinal muscular atrophy analysis using long-read PacBio
390 HiFi sequencing. *Am J Hum Genet* 110: 240-250.
391 <https://doi.org/10.1016/j.ajhg.2023.01.001>
- 392 Chung CCY, Hue SPY, Ng NYT, Doong PHL, Hong Kong Genome P, Chu ATW, Chung
393 BHY (2023) Meta-analysis of the diagnostic and clinical utility of exome and
394 genome sequencing in pediatric and adult patients with rare diseases across
395 diverse populations. *Genet Med* 25: 100896.
396 <https://doi.org/10.1016/j.gim.2023.100896>
- 397 Conlin LK, Aref-Eshghi E, McEldrew DA, Luo M, Rajagopalan R (2022) Long-read
398 sequencing for molecular diagnostics in constitutional genetic disorders. *Hum*
399 *Mutat* 43: 1531-1544. <https://doi.org/10.1002/humu.24465>
- 400 Downie L, Halliday J, Burt R, Lunke S, Lynch E, Martyn M, Poulakis Z, Gaff C, Sung V,
401 Wake M, Hunter MF, Saunders K, Rose E, Lewis S, Jarmolowicz A, Phelan D,

402 Rehm HL, Melbourne Genomics Health A, Amor DJ (2020) Exome sequencing in
403 infants with congenital hearing impairment: a population-based cohort study. *Eur*
404 *J Hum Genet* 28: 587-596. <https://doi.org/10.1038/s41431-019-0553-8>
405 Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO,
406 Marchini JL, McCarthy S, McVean GA, Abecasis GR (2015) A global reference for
407 human genetic variation. *Nature* 526: 68-74. <https://doi.org/10.1038/nature15393>
408 Han S, Zhang D, Guo Y, Fu Z, Guan G (2021) Prevalence and Characteristics of STRC
409 Gene Mutations (DFNB16): A Systematic Review and Meta-Analysis. *Front Genet*
410 12: 707845. <https://doi.org/10.3389/fgene.2021.707845>
411 Holt JM, Saunders CT, Rowell WJ, Kronenberg Z, Wenger AM, Eberle M (2024) HiPhase:
412 jointly phasing small, structural, and tandem repeat variants from HiFi sequencing.
413 *Bioinformatics* 40. <https://doi.org/10.1093/bioinformatics/btae042>
414 Kim YS, Kim Y, Jeon HW, Yi N, Lee SY, Kim Y, Han JH, Kim MY, Kim BH, Choi HY,
415 Carandang M, Koo JW, Kim BJ, Bae YJ, Choi BY (2022) Full etiologic spectrum of
416 pediatric severe to profound hearing loss of consecutive 119 cases. *Sci Rep* 12:
417 12335. <https://doi.org/10.1038/s41598-022-16421-x>
418 Lv J, Wang H, Cheng X, Chen Y, Wang D, Zhang L, Cao Q, Tang H, Hu S, Gao K, Xun
419 M, Wang J, Wang Z, Zhu B, Cui C, Gao Z, Guo L, Yu S, Jiang L, Yin Y, Zhang J,
420 Chen B, Wang W, Chai R, Chen ZY, Li H, Shu Y (2024) AAV1-hOTOF gene therapy
421 for autosomal recessive deafness 9: a single-arm trial. *Lancet* 403: 2317-2325.
422 [https://doi.org/10.1016/S0140-6736\(23\)02874-X](https://doi.org/10.1016/S0140-6736(23)02874-X)
423 Mahmoud M, Huang Y, Garimella K, Audano PA, Wan W, Prasad N, Handsaker RE, Hall
424 S, Pionzio A, Schatz MC, Talkowski ME, Eichler EE, Levy SE, Sedlazeck FJ (2024)
425 Utility of long-read sequencing for All of Us. *Nat Commun* 15: 837.
426 <https://doi.org/10.1038/s41467-024-44804-3>
427 Malinowski J, Miller DT, Demmer L, Gannon J, Pereira EM, Schroeder MC, Scheuner MT,
428 Tsai AC, Hickey SE, Shen J, Practice AP, Guidelines C (2020) Systematic
429 evidence-based review: outcomes from exome and genome sequencing for
430 pediatric patients with congenital anomalies or intellectual disability. *Genet Med*
431 22: 986-1004. <https://doi.org/10.1038/s41436-020-0771-z>
432 Manickam K, McClain MR, Demmer LA, Biswas S, Kearney HM, Malinowski J,
433 Massingham LJ, Miller D, Yu TW, Hisama FM, Directors ABo (2021) Exome and
434 genome sequencing for pediatric patients with congenital anomalies or intellectual
435 disability: an evidence-based clinical guideline of the American College of Medical
436 Genetics and Genomics (ACMG). *Genet Med* 23: 2029-2037.
437 <https://doi.org/10.1038/s41436-021-01242-6>
438 Mantere T, Kersten S, Hoischen A (2019) Long-Read Sequencing Emerging in Medical
439 Genetics. *Front Genet* 10: 426. <https://doi.org/10.3389/fgene.2019.00426>
440 Miller DE, Sulovari A, Wang T, Loucks H, Hoekzema K, Munson KM, Lewis AP, Fuerte
441 EPA, Paschal CR, Walsh T, Thies J, Bennett JT, Glass I, Dipple KM, Patterson K,
442 Bonkowski ES, Nelson Z, Squire A, Sikes M, Beckman E, Bennett RL, Earl D, Lee
443 W, Allikmets R, Perlman SJ, Chow P, Hing AV, Wenger TL, Adam MP, Sun A, Lam
444 C, Chang I, Zou X, Austin SL, Huggins E, Safi A, Iyengar AK, Reddy TE, Majoros
445 WH, Allen AS, Crawford GE, Kishnani PS, University of Washington Center for
446 Mendelian G, King MC, Cherry T, Chong JX, Bamshad MJ, Nickerson DA, Mefford
447 HC, Doherty D, Eichler EE (2021) Targeted long-read sequencing identifies

- 448 missing disease-causing variation. *Am J Hum Genet* 108: 1436-1449.
449 <https://doi.org/10.1016/j.ajhg.2021.06.006>
- 450 Morton CC, Nance WE (2006) Newborn hearing screening--a silent revolution. *N Engl J*
451 *Med* 354: 2151-64. <https://doi.org/10.1056/NEJMra050700>
- 452 Ohori S, Tsuburaya RS, Kinoshita M, Miyagi E, Mizuguchi T, Mitsunashi S, Frith MC,
453 Matsumoto N (2021) Long-read whole-genome sequencing identified a partial
454 MBD5 deletion in an exome-negative patient with neurodevelopmental disorder. *J*
455 *Hum Genet* 66: 697-705. <https://doi.org/10.1038/s10038-020-00893-8>
- 456 Olivucci G, Iovino E, Innella G, Turchetti D, Pippucci T, Magini P (2024) Long read
457 sequencing on its way to the routine diagnostics of genetic diseases. *Front Genet*
458 15: 1374860. <https://doi.org/10.3389/fgene.2024.1374860>
- 459 Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin
460 A, Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M, Booth KT,
461 Azaiez H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou Tayoun AN,
462 ClinGen Hearing Loss Clinical Domain Working G (2018) Expert specification of
463 the ACMG/AMP variant interpretation guidelines for genetic hearing loss. *Hum*
464 *Mutat* 39: 1593-1613. <https://doi.org/10.1002/humu.23630>
- 465 Pagnamenta AT, Camps C, Giacomuzzi E, Taylor JM, Hashim M, Calpena E, Kaisaki PJ,
466 Hashimoto A, Yu J, Sanders E, Schwessinger R, Hughes JR, Lunter G, Dreau H,
467 Ferla M, Lange L, Kesim Y, Ragoussis V, Vavoulis DV, Allroggen H, Ansorge O,
468 Babbs C, Banka S, Banos-Pinero B, Beeson D, Ben-Ami T, Bennett DL, Bento C,
469 Blair E, Brasch-Andersen C, Bull KR, Cario H, Cilliers D, Conti V, Davies EG,
470 Dhalla F, Dacal BD, Dong Y, Dunford JE, Guerrini R, Harris AL, Hartley J, Hollander
471 G, Javaid K, Kane M, Kelly D, Knight SJL, Kreins AY, Kvikstad EM,
472 Langman CB, Lester T, Lines KE, Lord SR, Lu X, Mansour S, Manzur A, Maroofian
473 R, Marsden B, Mason J, McGowan SJ, Mei D, Mlcochova H, Murakami Y, Nemeth
474 AH, Okoli S, Ormondroyd E, Ousager LB, Palace J, Patel SY, Pentony MM, Pugh
475 C, Rad A, Ramesh A, Riva SG, Roberts I, Roy N, Salminen O, Schilling KD, Scott
476 C, Sen A, Smith C, Stevenson M, Thakker RV, Twigg SRF, Uhlig HH, van Wijk R,
477 Vona B, Wall S, Wang J, Watkins H, Zak J, Schuh AH, Kini U, Wilkie AOM, Popitsch
478 N, Taylor JC (2023) Structural and non-coding variants increase the diagnostic
479 yield of clinical whole genome sequencing for rare diseases. *Genome Med* 15: 94.
480 <https://doi.org/10.1186/s13073-023-01240-0>
- 481 Perry J, Redfield S, Oza A, Rouse S, Stewart C, Khela H, Srinivasan T, Albano V, Shearer
482 E, Kenna M (2023) Exome Sequencing Expands the Genetic Diagnostic Spectrum
483 for Pediatric Hearing Loss. *Laryngoscope* 133: 2417-2424.
484 <https://doi.org/10.1002/lary.30507>
- 485 Poplin R, Chang PC, Alexander D, Schwartz S, Colthurst T, Ku A, Newburger D, Dijamco
486 J, Nguyen N, Afshar PT, Gross SS, Dorfman L, McLean CY, DePristo MA (2018) A
487 universal SNP and small-indel variant caller using deep neural networks. *Nat*
488 *Biotechnol* 36: 983-987. <https://doi.org/10.1038/nbt.4235>
- 489 Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, Vertino-Bell A, Smaoui N,
490 Neidich J, Monaghan KG, McKnight D, Bai R, Suchy S, Friedman B, Tahiliani J,
491 Pineda-Alvarez D, Richard G, Brandt T, Haverfield E, Chung WK, Bale S (2016)
492 Clinical application of whole-exome sequencing across clinical indications. *Genet*
493 *Med* 18: 696-704. <https://doi.org/10.1038/gim.2015.148>

- 494 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon
495 E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and
496 guidelines for the interpretation of sequence variants: a joint consensus
497 recommendation of the American College of Medical Genetics and Genomics and
498 the Association for Molecular Pathology. *Genet Med* 17: 405-24.
499 <https://doi.org/10.1038/gim.2015.30>
- 500 Rockowitz S, LeCompte N, Carmack M, Quitadamo A, Wang L, Park M, Knight D, Sexton
501 E, Smith L, Sheidley B, Field M, Holm IA, Brownstein CA, Agrawal PB, Kornetsky
502 S, Poduri A, Snapper SB, Beggs AH, Yu TW, Williams DA, Sliz P (2020) Children's
503 rare disease cohorts: an integrative research and clinical genomics initiative. *NPJ*
504 *Genom Med* 5: 29. <https://doi.org/10.1038/s41525-020-0137-0>
- 505 Rouse SL, Florentine MM, Taketa E, Chan DK (2022) Racial and ethnic disparities in
506 genetic testing for hearing loss: a systematic review and synthesis. *Hum Genet*
507 141: 485-494. <https://doi.org/10.1007/s00439-021-02335-7>
- 508 Shearer AE (2024) Genetic testing for pediatric sensorineural hearing loss in the era of
509 gene therapy. *Curr Opin Otolaryngol Head Neck Surg*.
510 <https://doi.org/10.1097/MOO.0000000000001005>
- 511 Shearer AE, Kolbe DL, Azaiez H, Sloan CM, Frees KL, Weaver AE, Clark ET, Nishimura
512 CJ, Black-Ziegelbein EA, Smith RJ (2014) Copy number variants are a common
513 cause of non-syndromic hearing loss. *Genome Med* 6: 37.
514 <https://doi.org/10.1186/gm554>
- 515 Shubina-Oleinik O, Nist-Lund C, French C, Rockowitz S, Shearer AE, Holt JR (2021)
516 Dual-vector gene therapy restores cochlear amplification and auditory sensitivity
517 in a mouse model of DFNB16 hearing loss. *Sci Adv* 7: eabi7629.
518 <https://doi.org/10.1126/sciadv.abi7629>
- 519 Sloan-Heggen CM, Bierer AO, Shearer AE, Kolbe DL, Nishimura CJ, Frees KL, Ephraim
520 SS, Shibata SB, Booth KT, Campbell CA, Ranum PT, Weaver AE, Black-Ziegelbein
521 EA, Wang D, Azaiez H, Smith RJH (2016) Comprehensive genetic testing in the
522 clinical evaluation of 1119 patients with hearing loss. *Hum Genet* 135: 441-450.
523 <https://doi.org/10.1007/s00439-016-1648-8>
- 524 Smith RJ, Bale JF, Jr., White KR (2005) Sensorineural hearing loss in children. *Lancet*
525 365: 879-90. [https://doi.org/10.1016/S0140-6736\(05\)71047-3](https://doi.org/10.1016/S0140-6736(05)71047-3)
- 526 Stefanski A, Calle-Lopez Y, Leu C, Perez-Palma E, Pestana-Knight E, Lal D (2021)
527 Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual
528 disability: A systematic review and meta-analysis. *Epilepsia* 62: 143-151.
529 <https://doi.org/10.1111/epi.16755>
- 530 Vache C, Puechberty J, Faugere V, Darmaisin F, Liquori A, Baux D, Blanchet C, Garcia-
531 Garcia G, Meunier I, Pellestor F, Koenig M, Roux AF (2020) A 4.6 Mb Inversion
532 Leading to PCDH15-LINC00844 and BICC1-PCDH15 Fusion Transcripts as a
533 New Pathogenic Mechanism Implicated in Usher Syndrome Type 1. *Front Genet*
534 11: 623. <https://doi.org/10.3389/fgene.2020.00623>
- 535 Vandersluis S, M.L. C, L. C, O. G-V, D. W, C. H (2020) Genome-Wide Sequencing for
536 Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A
537 Health Technology Assessment. *Ont Health Technol Assess Ser* 20: 1-178.
- 538 Vollger MR, Dishuck PC, Harvey WT, DeWitt WS, Guitart X, Goldberg ME, Rozanski AN,
539 Lucas J, Asri M, Human Pangenome Reference C, Munson KM, Lewis AP,

540 Hoekzema K, Logsdon GA, Porubsky D, Paten B, Harris K, Hsieh P, Eichler EE
541 (2023) Increased mutation and gene conversion within human segmental
542 duplications. *Nature* 617: 325-334. <https://doi.org/10.1038/s41586-023-05895-y>
543 Vollger MR, Guitart X, Dishuck PC, Mercuri L, Harvey WT, Gershman A, Diekhans M,
544 Sulovari A, Munson KM, Lewis AP, Hoekzema K, Porubsky D, Li R, Nurk S, Koren
545 S, Miga KH, Phillippy AM, Timp W, Ventura M, Eichler EE (2022) Segmental
546 duplications and their variation in a complete human genome. *Science* 376:
547 eabj6965. <https://doi.org/10.1126/science.abj6965>
548 Wojcik MH, Lemire G, Berger E, Zaki MS, Wissmann M, Win W, White SM, Weisburd B,
549 Wiczorek D, Waddell LB, Verboon JM, VanNoy GE, Topf A, Tan TY, Syrbe S,
550 Strehlow V, Straub V, Stenton SL, Snow H, Singer-Berk M, Silver J, Shril S, Seaby
551 EG, Schneider R, Sankaran VG, Sanchis-Juan A, Russell KA, Reinson K,
552 Ravenscroft G, Radtke M, Popp D, Polster T, Platzer K, Pierce EA, Place EM,
553 Pajusalu S, Pais L, Ounap K, Osei-Owusu I, Opperman H, Okur V, Oja KT, O'Leary
554 M, O'Heir E, Morel CF, Merckenschlager A, Marchant RG, Mangilog BE, Madden
555 JA, MacArthur D, Lovgren A, Lerner-Ellis JP, Lin J, Laing N, Hildebrandt F,
556 Hentschel J, Groopman E, Goodrich J, Gleeson JG, Ghaoui R, Genetti CA,
557 Gburek-Augustat J, Gazda HT, Ganesh VS, Ganapathi M, Gallacher L, Fu JM,
558 Evangelista E, England E, Donkervoort S, DiTroia S, Cooper ST, Chung WK,
559 Christodoulou J, Chao KR, Cato LD, Bujakowska KM, Bryen SJ, Brand H,
560 Bonnemann CG, Beggs AH, Baxter SM, Bartolomaeus T, Agrawal PB, Talkowski
561 M, Austin-Tse C, Abou Jamra R, Rehm HL, O'Donnell-Luria A (2024) Genome
562 Sequencing for Diagnosing Rare Diseases. *N Engl J Med* 390: 1985-1997.
563 <https://doi.org/10.1056/NEJMoa2314761>
564 Xie Z, Sun C, Zhang S, Liu Y, Yu M, Zheng Y, Meng L, Acharya A, Comejo-Sanchez DM,
565 Wang G, Zhang W, Schrauwen I, Leal SM, Wang Z, Yuan Y (2020) Long-read
566 whole-genome sequencing for the genetic diagnosis of dystrophinopathies. *Ann*
567 *Clin Transl Neurol* 7: 2041-2046. <https://doi.org/10.1002/acn3.51201>
568


570 **Figures**

571

572 **Figure 1 Causative variants identified via long-read genome sequencing (lrGS).** A) Top panel shows identification of
 573 compound heterozygous pathogenic variant and hemizygous deletion in *STRC*. Bottom panel shows haplotype analysis
 574 indicating two *STRCP1* haplotypes and only one *STRC* haplotype, with roughly half of the expected coverage (CN1),
 575 containing a G>A stop gain at chr15:43,616,338. B) Identification of a single exon deletion (exon 22) and stop mutation in
 576 compound heterozygosity in the *OTOA* gene. C) Identification of a copy-neutral inversion in the *MITF* gene.

577

578



579

580 **Tables**

581

582 **Table 1:** Cohort demographic and clinical characteristics. IrGS: long-read genome
583 sequencing.

584

Characteristic	IrGS Cohort n (%)
Total	19 (100%)
Sex	
Female	13 (68.4%)
Male	6 (31.6%)
Race	
White	16 (82.4%)
Not Reported	1 (5.2%)
Asian	1 (5.2%)
Hispanic/Latino	1 (5.2%)
Positive Family History (of childhood-onset HL)	
No	15 (78.9%)
Yes	4 (21.1%)
HL Onset	
Congenital	12 (63.1%)
Prelingual	2 (10.5%)
Postlingual	3 (15.8%)
Unknown	2 (10.5%)
HL Laterality	
Bilateral, symmetric	15 (78.9%)
Unilateral	1 (5.2%)
Bilateral, asymmetric	3 (15.8%)
HL Severity (in worse ear)	
Mild-Moderate	9 (47.4%)
Severe-Profound	10 (52.6%)
Syndromic Features	
Yes	5 (26.3%)
No	14 (73.7%)
Previous Genetic Testing	
Single gene	3 (15.8%)
Gene panel	4 (21.1%)
Exome sequencing	19 (100%)
Short read genome sequencing	18 (94.7%)

585

586 **Table 2.** Key sequencing statistics using exome sequencing (ES), short-read genome sequencing (srGS) and long-read
 587 genome sequencing (lrGS).
 588

Method	ES	srGS	PacBio lrGS
N Samples	19	18	19
Read Length (bp)	150	150	13,539
Avg Depth of Coverage	75.5	50.9	29.5
SNV Detected (T-test* significance relative to lrGS)	117,336** (p=4.2E-36)	5,039,980 (p=1.2E-18)	5,386,525
SV Detected (T-test* significance relative to lrGS)	78† (p=1.5E-28)	12,273 (p=6.6E-15)	22,004

589
 590 SNV = single nucleotide variant, SV = structural variant. *Two-tailed paired T-test. **T-test significance ES relative to srGS
 591 for SNVs: 5.1E-34. †T-test significance ES relative to srGS for SVs: 9.6E-17.
 592

593 **Statements and Declarations**

594 **Acknowledgments**

595 We thank the families for their participation.

596 **Funding**

597 This work was funded by NIDCD K08 DC19716 and by Escuchar Sin Fronteras Foundation to AES with support from the
598 Boston Children's Hospital Rare Disease Cohort Initiative.

599

600 **Author contributions**

601 AES and SER conceived the study. CTS and JMH contributed software. AES, CEF, CN, SER, WJR, and WS performed
602 formal analyses that were validated by AES, CEF, SER, and WS. MZ, AP, CF, CL, EML, SER, and TS conducted the
603 investigation process. AES, MK, and SER secured patient resources. AES, CEF, SER, and WS performed data curation.
604 AES and SER wrote the original draft. AES, CEF, CN, EML, MK, SR, SER, WJR, and WS contributed to reviewing and
605 editing. AES and SER prepared figures. AES, ME, MK, and SR provided supervision. SER, SR, and CEF contributed to
606 project administration. All authors reviewed and approved of the manuscript.

607 **Data Availability**

608 Most data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional
609 data related to this paper may be requested from the authors.

610 **Compliance with ethical standards**

611 **Conflict of interest**

612 AES is the principal investigator of an investigator initiated clinical trial, Genetic Newborn Hearing Screening, funded by
613 Akouos/Eli Lilly; the site principal investigator of the sponsored Phase I/II clinical trial *OTOF* gene therapy with Akouos/Eli
614 Lilly; and on the advisory board without compensation for Akouos/Eli Lilly and Decibel/Akouos. WJR, CN, JMH, CTS, CF,
615 EML, CL, and MAE are employees and shareholders of PacBio. The other authors have no conflicts of interest to declare.

616 **Ethics approval**

617 This study was approved by the institutional review board of Boston Children's Hospital (IRB P00035179 and P00031494)

618

619 **Consent to participate**

620 Written informed consent was obtained from all participants.

621 **Consent to publish**

622 Consent to publish was obtained from all participants.